Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 130 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pexastimogene devacirepvec (pexa-vec) for hepatocellular carcinoma – first line Pexastimogene devacirepvec (Pexa-vec; JX-594) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma‐ second line and beyond Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Ponesimod for Relapsing-remitting Multiple Sclerosis Ponesimod (ACT-128800; RG-3477) Multiple sclerosis (MS) Neurology 2017 View  |  Download
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy 5-Fluorouracil , Capecitabine (Xeloda) , Cisplatin (Platinol) , Ramucirumab (Cyramza) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus REX-001 (Rexmyelocel-T) Critical limb ischaemia (CLI) Cardiovascular System 2017 View  |  Download
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs Risankizumab (BI 655066; Skyrizi; ABBV 066) Psoriatic arthritis Dermatology , Rheumatology 2017 View  |  Download
Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis Risankizumab (BI 655066; Skyrizi; ABBV 066) Plaque psoriasis Dermatology 2017 View  |  Download
Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) Rituximab (MabThera; Rituxan; RG 105) Granulomatosis with polyangiitis (GPA) , Microscopic polyangiitis (MPA) Cardiovascular System 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications